Sensitization to repeated morphine injection in the rat: possible involvement of A10 dopamine neurons

Daily administration of morphine in rats produces an increase in the motor stimulant effect of subsequent morphine injections. This study was designed to characterize the behavioral sensitization produced by daily morphine and to evaluate the involvement of the mesolimbic and/or mesocortical dopamine (DA) neurons. Daily injection of morphine for 7 days produced an increase in both horizontal and vertical photocell counts. There was no difference in morphine levels in the blood or brain between daily morphine- and daily saline-treated rats at 30 or 90 min after acute injection of morphine. The increase was present for 60 days after initiating treatment and was associated with increases in locomotion, rearing, sniffing, grooming and bursting. Sensitization to morphine was prevented by pretreatment with naloxone i.p. or naltrexone methobromide injection into the ventral tegmental area (VTA; location of A10 DA perikarya projecting to limbic and cortical areas). In contrast, pretreatment with the same dose of naltrexone methobromide injected into the nucleus accumbens (limbic DA terminal field) or lateral ventricles did not significantly attenuate behavioral sensitization to morphine. Daily intra-VTA injections of the mu opioid agonist Tyr-D-Ala-Gly-NMe-Phe-Gly-ol enhanced the behavioral stimulant effect of acute morphine. The effects of daily morphine treatment on DA systems were evaluated by measuring DA metabolism, dopa accumulation and DA depletion in the VTA and various DA terminal fields including the prefrontal cortex, nucleus accumbens and striatum.(ABSTRACT TRUNCATED AT 250 WORDS)     

Sensitization to repeated enkephalin administration into the ventral tegmental area of the rat. II. Involvement of the mesolimbic dopamine system

In the preceding report it was shown that daily microinjection with the enkephalin analog, D-Ala2-Met5-enkephalinamide (DALA), into the ventral tegmental area (VTA) results in a progressive increase in spontaneous motor activity. In this study it was found that the enhanced behavioral response was associated with a greater increase in dopamine metabolism in the nucleus accumbens and striatum after acute DALA administration. However, daily injection with either DALA or saline did not alter the steady-state levels of dopamine or its metabolites. Haloperidol did not block the development of an augmented behavioral response. Rats pretreated with daily intra-VTA injections of DALA had a significantly greater motor response to amphetamine, i.p. or neurotensin, intra-VTA, when compared with rats pretreated with daily saline. However, the motor effects of caffeine or intraaccumbens injection with dopamine were not altered by daily injections. These data support the idea that daily intra-VTA injection with DALA results in an increased responsiveness of mesolimbic dopamine neurons to excitatory pharmacological stimuli.     

Sensitization to repeated enkephalin administration into the ventral tegmental area of the rat. I. Behavioral characterization

Acute injection with the enkephalin analog, D-Ala2-Met5-enkephalinamide (DALA), into the ventral tegmental area (VTA) of the rat will elicit behavioral hyperactivity. In this study it was found that daily intra-VTA injection with DALA results in a progressively enhanced motor response. The augmented behavioral response was dose-related, occurring at a threshold dose between 0.3 and 1.0 microgram of DALA per side. It consisted of a significant increase in locomotion and bursting, and a decrease in the occurrence of sleep/still. The augmented motor response did not result from decreased elimination of microinjected DALA from the VTA. Naloxone blocked the development of an enhanced motor response, as did substitution with the putative kappa opioid agonist, dynorphin. However, the sensitization to DALA was retained when the delta opioid agonist, D-Ala2-D-Leu5-enkephalin, was substituted for DALA and partial sensitization occurred when the mu opioid agonist, morphine, was substituted for DALA. Conditioning to the behavioral apparatus was not found to play a role in the sensitization to DALA. These data demonstrate that daily exposure of neurons in the VTA to enkephalin analogs results in a semipermanent alteration in the response of these neurons to subsequent injections with enkephalin analogs.     

Necessary role for ventral tegmental area adenylate cyclase and protein kinase A in induction of behavioral sensitization to intraventral tegmental area amphetamine

In the present study, we investigated the effects of selective activation or inhibition of ventral tegmental area (VTA) adenylate cyclase (AC) and protein kinase A (PKA) on long-term sensitization induced by repeated intra-VTA or peripheral amphetamine (AMPH). Selective inhibition of AC by SQ 22,536 (9-(tetrahydro-2-furanyl)-9H-purin-6-amine; 100 nmol/side bilateral into VTA) had no effect on acute basal locomotion but attenuated the locomotor stimulation induced by acute i.p. AMPH (1.5 mg/kg). Coinjection of SQ 22,536 (100 nmol/side) fully blocked the sensitization induced by repeated intra-VTA AMPH (15 nmol/side) but had no detectable effect on the sensitization induced by repeated i. p. AMPH. Persistent activation of AC by intra-VTA cholera toxin (500 ng/side) modestly increased acute locomotion and induced a robust sensitization to i.p. AMPH challenge 10 days after the last of three repeated VTA microinjections. Selective inhibition of PKA by Rp-adenosine-3',5'-cyclic monophosphothioate triethylamine (Rp-cAMPS; 25 nmol/side) had no effect on acute basal or AMPH-stimulated locomotion. Coinjection of Rp-cAMPS (25 nmol/side) fully blocked the sensitization induced by repeated intra-VTA AMPH but had no effect on sensitization induced by repeated i.p. AMPH. Intra-VTA microinjection of the selective PKA activator Sp-adenosine-3',5'-cyclic monophosphothioate triethylamine (Sp-cAMPS; 25-100 nmol/side) dose-dependently stimulated acute locomotion and exerted synergistic effects on locomotor activity when coinfused into the VTA with AMPH but had no detectable effect on acute i.p. AMPH-induced locomotion. Repeated intra-VTA Sp-cAMPS did not induce sensitization to AMPH challenge but potentiated the sensitization induced by repeated i.p. AMPH. These results suggest that VTA cAMP signal transduction is necessary for the induction of persistent sensitization to intra-VTA amphetamine and that peripheral and intra-VTA AMPH may not induce behavioral sensitization by identical mechanisms.     

GABA(B) receptor activation in the ventral tegmental area inhibits the acquisition and expression of opiate-induced motor sensitization

Opiate-induced motor sensitization refers to the progressive and enduring motor response that develops after intermittent drug administration, and results from neuroadaptive changes in ventral tegmental area (VTA) and nucleus accumbens (NAc) neurons. Repeated activation of mu-opioid receptors localized on gamma-aminobutyric acid (GABA) neurons in the VTA enhances dopaminergic cell activity and stimulates dopamine release in the nucleus accumbens. We hypothesize that GABA(B) receptor agonist treatment in the VTA blocks morphine-induced motor stimulation, motor sensitization, and accumbal Fos immunoreactivity by inhibiting the activation of dopaminergic neurons. First, C57BL/6 mice were coadministered a single subcutaneous injection of morphine with intra-VTA baclofen, a GABA(B) receptor agonist. Baclofen produced a dose-dependent inhibition of opiate-induced motor stimulation that was attenuated by 2-hydroxysaclofen, a GABA(B) receptor antagonist. Next, morphine was administered on days 1, 3, 5, and 9 and mice demonstrated sensitization to its motor stimulant effects and concomitant induction of Fos immunoreactivity in the NAc shell (NAcS) but not NAc core. Intra-VTA baclofen administered during morphine pretreatment blocked the acquisition of morphine-induced motor sensitization and Fos activation in the NAcS. Intra-VTA baclofen administered only on day 9 blocked the expression of morphine-induced motor sensitization and Fos activation in the NAcS. A linear relationship was found between morphine-induced motor activity and accumbal Fos in single- and repeated-dose treatment groups. In conclusion, GABA(B) receptor stimulation in the VTA blocked opiate-induced motor stimulation and motor sensitization by inhibiting the activation of NAcS neurons. GABA(B) receptor agonists may be useful pharmacological treatments in altering the behavioral effects of opiates.     

Neuromedin N mimics the actions of neurotensin in the ventral tegmental area but not in the nucleus accumbens

Neuromedin N (NN) is a hexapeptide recently isolated from porcine spinal cord that shares a four-amino acid homology with the C-terminus of the biologically active tridecapeptide neurotensin (NT). Microinjection with NT into the ventral tegmental area or nucleus accumbens of rats has been shown to increase locomotor activity and dopamine (DA) metabolism in some limbic areas or to inhibit the motor stimulant effect of intra-accumbens administration of DA, respectively. In this study the effects of microinjected NN were compared with those of NT. After injection into the ventral tegmental area, NN was shown to be more potent than NT at increasing spontaneous motor activity and to produce an increase in DA metabolism in the nucleus accumbens, prefrontal cortex, diagonal band of Broca and septum. However, when injected into the nucleus accumbens, NN was markedly less potent than NT at inhibiting DA-induced behavioral hyperactivity. In addition to DA-related effects, i.c.v. injection with NT causes hypothermia, and i.c.v. administration with NN was without effect on colonic temperature. These data demonstrate that NN has a behavioral profile distinct from that of NT.     

Behavioral and neurochemical effects of acute and daily cocaine administration in rats

Daily cocaine injection into rodents produces a progressive increase in the motor stimulant effect of acute cocaine administration. In this study it was found that daily cocaine injection (15 mg/kg i.p. x 3 days) produced an enhanced motor stimulant response to acute cocaine injection. The behavioral augmentation was linear with regards to dose in horizontal activity and behavioral intensity rating, but was biphasic in vertical activity. Augmented vertical, but not horizontal, activity in response to acute cocaine was found to persist for 2 weeks after the last daily injection of cocaine. Acute injection of cocaine was found to significantly decrease the level of dopamine (DA) metabolites in the nucleus accumbens, striatum and A10 DA region. In rats pretreated with daily injections of cocaine (15 mg/kg i.p. x 3 days), an acute challenge of cocaine 14 days after the last daily injection produced a more consistent decrease in DA metabolites in the nucleus accumbens, striatum and prefrontal cortex compared to daily saline-pretreated rats. In contrast, daily cocaine treatment abolished the decrease in DA metabolites produced in the A10 region by an acute cocaine challenge. Acute injection with cocaine was found to significantly depress dopa accumulation in the A10 region, nucleus accumbens and striatum. This effect was abolished in the A10 region in rats pretreated 14 days previously with daily injections of cocaine (7.5, 15.0 or 30 mg/kg i.p. x 3 days), but remained intact in the nucleus accumbens and striatum, except after daily pretreatment with the highest dose of cocaine.(ABSTRACT TRUNCATED AT 250 WORDS)     

Modulation of mesoprefrontal dopamine neurons by central benzodiazepine receptors. I. Pharmacological characterization

The benzodiazepine (BZ) recognition sites on the gamma-aminobutyric acid receptor/chloride ionophore complex have been suggested to be involved in the modulation of mesoprefrontal dopamine (DA) neurons. We have examined further the effects of different classes of BZ receptor ligands on DA metabolism in the prefrontal cortex. The anxiogenic inverse agonist FG 7142 elevated selectively 3,4-dihydroxyphenylacetic acid (DOPAC) levels and DO-PAC/DA ratio in the prefrontal cortex in a dose- and time-dependent manner. The activating effect was not, however, observed in any other mesocortical, mesolimbic or nigrostriatal DA terminal fields examined. Pretreatments with BZ agonists such as diazepam, flurazepam, lorazepam and CGS 9896 and BZ antagonists such as Ro15-1788 and CGS 8216 and barbiturates such as pentobarbital, significantly antagonized the beta-carboline-induced elevation of prefrontal DOPAC levels. Furthermore, a significant correlation was found between the pharmacological profile of different BZ receptor ligands on prefrontal DA metabolism and their profiles in behavioral, electrophysiological and receptor binding studies. Agonists increased DA levels and consequently decreased DOPAC/DA ratio in the prefrontal cortex. Inverse agonists, on the other hand, significantly elevated prefrontal DOPAC levels and DOPAC/DA ratio in a dose-dependent manner. Antagonists such as Ro15-1788 and CGS 8216, at low doses, did not alter mesoprefrontal DA metabolism, but at higher doses did elevate DOPAC/DA ratio in the prefrontal cortex.(ABSTRACT TRUNCATED AT 250 WORDS)     

Mu opioid receptor involvement in enkephalin activation of dopamine neurons in the ventral tegmental area

Many lines of evidence suggest that opioids act in the A10 dopamine (DA) region to activate DA neurons projecting to limbic terminal areas. Thus, injection of morphine and enkephalin analogs into the ventral tegmental area (a major subnucleus of the A10 DA region) produces an increase in spontaneous motor activity that is blocked by DA receptor antagonists and increases DA metabolism in the nucleus accumbens. The present study utilized enkephalin analogs specific for either the mu or delta opioid receptor to evaluate which receptor subtype(s) is activating the A10 DA neurons. It was found that the specific mu agonist, Try-D-Ala-Gly-NMe-Phe-Gly-ol, was significantly more potent than the specific delta agonist, [D-Pen2,5]-enkephalin, at increasing spontaneous motor activity or DA metabolism in the nucleus accumbens, septum, striatum and prefrontal cortex. Further, naloxonazine, a putative antagonist of the mu-1 isoreceptor, significantly attenuated the motor-stimulant effect and increase in DA metabolism produced by intra-ventral tegmental area injection of Tyr-D-Ala-Gly-NMe-Phe-Gly-ol. It was found that the disposition of microinjected Tyr-D-Ala-Gly-NMe-Phe-Gly-ol or [D-Pen2,5]-enkephalin was not responsible for the difference in their potency. It is concluded that the mu receptor and, perhaps, the mu-1 isoreceptor mediate a major portion of the activation of A10 DA neurons previously demonstrated with mixed mu and delta opioid agonists.     

Reboxetine modulates the firing pattern of dopamine cells in the ventral tegmental area and selectively increases dopamine availability in the prefrontal cortex

Central dopaminergic neurons have been suggested to be involved in the pathophysiology of several psychiatric disorders, including depression, and appear to be modulated by noradrenergic activity both at the nerve terminal level and at the somatodendritic level. In recent years reboxetine, a selective noradrenaline reuptake inhibitor that differs from tricyclic antidepressants by its low affinity for muscarinic, cholinergic and alpha(1)-adrenergic receptors, has been introduced clinically. In the present study the effect of reboxetine on the function of the mesolimbocortical dopamine system was investigated by means of single cell recording and microdialysis in rats following administration of reboxetine in doses that appear to yield clinically relevant plasma concentrations. Reboxetine (0.625--20 mg/kg intravenously) induced an increase in burst firing, but not in average firing frequency of dopamine (DA) cells in the ventral tegmental area (VTA). Moreover, reboxetine (0.15--13.5 mg/kg intraperitoneally) caused a significantly enhanced DA output in the medial prefrontal cortex, whereas no effect was observed in the nucleus accumbens. Local administration of reboxetine (333 microM, 60 min), by means of reversed microdialysis into these brain regions, caused a significant increase in DA output in both brain regions. However, local administration of reboxetine into the VTA (333 microM, 60 min) did not affect DA availability in these terminal areas. Our results imply that clinical treatment with reboxetine may result in facilitation of both prefrontal DA output and the excitability of VTA DA neurons, effects that may contribute to its antidepressant action, especially on drive and motivation.     

Complexity of VTA DA neural activities in response to PFC transection in nicotine treated rats

Background  

The dopaminergic (DA) neurons in the ventral tegmental area (VTA) are widely implicated in the addiction and natural reward circuitry of the brain. These neurons project to several areas of the brain, including prefrontal cortex (PFC), nucleus accubens (NAc) and amygdala. The functional coupling between PFC and VTA has been demonstrated, but little is known about how PFC mediates nicotinic modulation in VTA DA neurons. The objectives of this study were to investigate the effect of acute nicotine exposure on the VTA DA neuronal firing and to understand how the disruption of communication from PFC affects the firing patterns of VTA DA neurons.     

Acute administration of amphetamine: differential regulation of dopamine synthesis in dopamine projection fields.

In order to study the inhibitory mechanisms regulating dopamine (DA) synthesis in vivo, the effect of amphetamine in the presence and absence of selective D1 and D2-DA receptor antagonists was examined in various brain regions. In response to amphetamine (3 mg/kg s.c.) administration, DA synthesis in the striatum, but not the nucleus accumbens or the medial prefrontal cortex, exhibited a biphasic response (increased followed by decreased). The D1 selective antagonist, SCH 23390 (0.5 mg/kg s.c., 60 min), modestly increased DA synthesis (30%) in the striatum but not in the nucleus accumbens or the prefrontal cortex. However, pretreatment with the D1 DA receptor antagonist did not prevent the amphetamine-induced elevation of striatal DA synthesis 45 min after amphetamine administration. The D2 selective antagonist, eticlopride (2 mg/kg s.c., 60 min), increased DA synthesis in both the striatum and the nucleus accumbens but not in the prefrontal cortex. Although amphetamine alone increased DA synthesis only in the striatum, in the presence of D2-DA receptor blockade, amphetamine increased DA synthesis in the striatum, the nucleus accumbens and the medial prefrontal cortex. The results support the hypothesis that DA synthesis is differentially regulated by distinct inhibitory mechanisms depending on the projection field. The apparent differences in regulatory mechanisms may allow selective alteration of DA synthesis in one particular projection field, while other areas remain unaffected.     

Regulation of locomotor activity by metabotropic glutamate receptors in the nucleus accumbens and ventral tegmental area

Glutamatergic innervation of the ventral tegmental area (VTA) and the nucleus accumbens (NA) regulates locomotor activity. The present study was designed to evaluate the involvement of metabotropic glutamate receptors (mGluRs) in motor activity. Agonists selective for each of the three subgroups of mGluRs were microinjected into the VTA or NA, and motor activity was monitored. The group I agonist (S)-3,5-dihydroxyphenylglycine elicited a dose-dependent elevation in motor activity after microinjection into either the VTA or NA. The effect in the NA was blocked by the mGluR1-specific antagonist 7-(hydroxyimino)cyclopropa[b]chromen-1a-carboxylate ethyl ester. The group II agonist (2S,2'R,3'R)-2-(2',3'-dicarboxycyclopropyl)glycine also elicited a short-duration motor activation after microinjection into either structure. The dose response in the VTA was biphasic, and the coadministration of the group II/III-specific antagonist (RS)-alpha-methyl-4-phosphonophenylglycine partially blocked motor activation in both the NA and VTA. Although the group III agonist L-(+)-2-amino-4-phosphonobutyric acid produced a relatively modest behavioral stimulation after microinjection into the NA, it was without effect in the VTA. These data indicate a role for mGluR subgroups in the regulation of motor activity in the VTA and NA.     

Dopamine-independent locomotion following blockade of N-methyl-D-aspartate receptors in the ventral tegmental area.

Compounds acting in the ventral tegmental area to increase motor activity are thought to do so by activating mesolimbic dopamine transmission. The present report demonstrates that the microinjection of N-methyl-D-aspartate (NMDA) antagonists into the ventral tegmental area produces a dose-dependent increase in motor activity. This effect was not mimicked by antagonizing either alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid/kainate or metabotropic glutamate receptors in the ventral tegmental area. Three experiments were conducted that indicated that the capacity of NMDA receptor antagonists to elevate motor activity did not involve increased dopamine transmission. 1) The systemic administration of a D1 dopamine receptor antagonist did not inhibit the motor stimulant response to NMDA antagonist injection into the ventral tegmental area except at doses that also inhibited motor activity after an injection of saline into the ventral tegmental area. 2) Stimulating orphanin receptors in the ventral tegmental area selectively inhibits dopamine cells, and this did not alter NMDA antagonist-induced motor activity. Whereas, stimulating gamma-aminobutyric acid (GABA)(B) receptors hyperpolarizes both dopamine and GABA cells in the ventral tegmental area, and this abolished NMDA antagonist-induced motor activity. 3) The microinjection of an NMDA antagonist into the ventral tegmental area did not increase dopamine metabolism in dopamine terminal fields, including the accumbens, striatum, or prefrontal cortex. Also consistent with a lack of dopamine involvement, repeated administration of NMDA antagonist into the ventral tegmental area did not produce behavioral sensitization. These data identify a mechanism to elicit a motor stimulant response from the ventral tegmental area that does not involve activating dopamine transmission.     

Pharmacological evidence supporting a role for central corticotropin-releasing factor(2) receptors in behavioral,but not endocrine,response to environmental stress

Corticotropin-releasing factor (CRF) is one of the principle components of the stress response. The physiological effects of CRF are mediated by two receptor subtypes, CRF(1) and CRF(2). Recent data obtained with the selective CRF(2) antagonist antisauvagine-30 (ASV-30) has begun to suggest that both CRF receptor subtypes may play a role in stress-related behaviors. Exactly how these two receptor subtypes interact to modulate the behavioral and endocrine responses to stress is not clear, however. We have attempted to understand the role of the CRF(2) receptor in the behavioral and endocrine responses to stress by comparing the effects of ASV-30 with the mixed CRF(1)/CRF(2) receptor antagonist astressin. Centrally administered ASV-30 reduced anxiety-like behavior in BALB/c mice in three models of anxiety: marble burying [minimal effective dose (MED) = 3 nmol], open field (MED = 3 nmol), and elevated plus maze (MED = 0.1 nmol). ASV-30 did not change locomotor activity or the adrenocorticotropic hormone (ACTH) response to restraint stress. The potent mixed CRF(1)/CRF(2) antagonist astressin not only reduced anxiety-like behavior in all three models with equivalent potency but also blunted the ACTH response to restraint stress. Finally, the new selective CRF(2) receptor agonist urocortin-II produced a dose-dependent increase in anxiety-like behavior in the plus maze test. Therefore, our data suggest that the CRF(2) receptor plays a role in the behavioral, but not the hypothalamic-pituitary-adrenal axis, response to stress.     

Acute and chronic corticotropin-releasing factor 1 receptor blockade inhibits cocaine-induced dopamine release: correlation with dopamine neuron activity

Corticotropin-releasing factor (CRF) is a neuropeptide associated with the integration of the physiological and behavioral responses to stress. Recently, CRF1 receptor antagonists have been shown to decrease cocaine self-administration and inhibit stress-induced reinstatement of cocaine-seeking behavior. The exact mechanisms underlying this effect are not clear. Based on the large amount of literature demonstrating an association between dopaminergic neurotransmission and reward-related behavior, the aim of the present study was to examine the effects of acute versus chronic CRF1 receptor blockade on mesencephalic dopamine (DA) neuron activity (determined by in vivo extracellular recordings) and extracellular DA levels in the nucleus accumbens (Acb) (using in vivo microdialysis). In addition, the effect of CRF1 receptor antagonism on cocaine-induced DA overflow in the Acb was examined and correlated with DA neuron activity in the ventral tegmental area (VTA). Acute (but not chronic) CRF1 receptor blockade by CRA-0450 [1-[8-(2,4-dichlorophenyl)-2-methylquinolin-4-yl]-1,2,3,6-tetrahydropyridine-4-carboxamide benzenesulfonate] was found to significantly increase DA neuron population activity without affecting burst firing, average firing rate, or Acb DA levels. In addition, both acute and chronic CRF1 receptor antagonism significantly reduced cocaine-stimulated DA overflow in the Acb, and this reduction was correlated with an attenuated cocaine-induced inhibition of DA population activity. Taken as a whole, these data demonstrate that, although DA neuron population activity exhibits tolerance to chronic CRF1 receptor antagonism (by CRA-0450), tolerance does not develop to the selective inhibition of cocaine-induced DA release (in the Acb) and, as such, may be beneficial in the treatment of cocaine addiction.     

Enkephalin action on the mesolimbic system: a dopamine-dependent and a dopamine-independent increase in locomotor activity

Enkephalin has been identified by immunohistochemistry to be present in the vicinity of mesolimbic dopaminergic perikarya in the ventral tegmental area and axonal terminals in the nucleus accumbens. To evaluate the possibility that endogenous enkephalin may physiologically modulate the mesolimbic dopamine (DA) system, the effect of microinjection of the peptidase-resistant enkephalin analog, D-Ala2-Met5-enkephalinamide (DALA), in the ventral tegmental area and nucleus accumbens was examined. Locomotion and rearing behavior and alteration in concentration of DA and its metabolites in mesolimbic terminal areas were used to evaluate mesolimbic dopaminergic function. Microinjection of DALA into the ventral tegmental area produced a dose-dependent increase in locomotion and rearing which was antagonized by neuroleptic administration in the nucleus accumbens. Inasmuch as DALA administration into the ventral tegmentum was additive with a subthreshold dose of DA injected into the nucleus accumbens and produced a dose-related increase in 3,4-dihydroxyphenylacetic acid and the 3,4-dihydroxyphenylacetic acid/DA ratio, these data are consistent with the postulate that this treatment with DALA activates the mesolimbic DA system. DALA microinjection into the nucleus accumbens also produced a dose-dependent increase in locomotion and rearing. However, this behavioral effect was shown to be independent of the mesolimbic DA system because neither neuroleptic injection into the nucleus accumbens nor destruction of the mesolimbic DA system with 6-hydroxydopamine blocked the behavioral response produced by this treatment. Furthermore, DALA injection into the nucleus accumbens did not alter nucleus accumbens levels of DA or its metabolites at 15, 30 or 60 min after injection.(ABSTRACT TRUNCATED AT 250 WORDS)     

Effects of 4'-chloro-3 alpha-(diphenylmethoxy)-tropane on mesostriatal, mesocortical, and mesolimbic dopamine transmission: comparison with effects of cocaine

Increase in dopamine (DA) neurotransmission resulting from blockade of the DA transporter (DAT) after administration of cocaine is believed to play a major role in mediating its behavioral and reinforcing effects. Since it was hypothesized that drugs that block the DAT have cocaine-like behavioral effects, it was of interest to study in the present article the stimulant effects of cocaine on locomotor activity and on pattern of activation of DA neurotransmission in different DAergic terminal areas in rats and compare these effects with those of 4'-chloro-3alpha-(diphenylmethoxy)-tropane (4-Cl-BZT), a benztropine analog showing higher affinity for the DAT, but reduced behavioral effects compared with cocaine. Administration of cocaine resulted in a dose-dependent stimulation of locomotor activity and DA neurotransmission in the nucleus accumbens shell and core, dorsal caudate, and in the medial prefrontal cortex (PFCX) measured by microdialysis. At comparable doses, the effects of 4-Cl-BZT on DA levels in all brain areas except the PFCX were generally reduced compared with those of cocaine, as were the effects on locomotor activity. The differences in behavioral effects corresponded generally to differences between the drugs with regard to their stimulation of extracellular DA levels, although the mechanism(s) for the differences in extracellular DA may involve effects mediated by sites other than the DAT or differences in the efficiency of the two drugs in blocking DA uptake. Nonetheless, the present results suggest that the differences in behavioral effects between cocaine and 4-Cl-BZT are related to differences in their patterns of activation of DA transmission.     

Affective Analgesia Following Muscarinic Activation of the Ventral Tegmental Area in Rats

Cholinergic stimulation of dopamine neurons in the ventral tegmental area (VTA) underlies activation of the brain reward circuitry. Activation of this circuit is proposed to preferentially suppress the affective reaction to noxious stimulation. Vocalization afterdischarges (VADs) are a validated model of the affective response of rats to noxious tail shock. The antinociceptive action of the acetylcholine agonist carbachol microinjected into the VTA on VAD threshold was compared with its effect on the thresholds of other tail shock–elicited responses (VDS, vocalizations during shock; SMR, spinal motor reflexes). Whereas VADs are organized within the forebrain, VDSs and SMRs are organized at medullary and spinal levels of the neuraxis, respectively. Carbachol (1 μg, 2 μg, and 4 μg) injected into VTA produced dose-dependent increases in VAD and VDS thresholds, although increases in VAD threshold were significantly greater than increases in VDS threshold. Administration of carbachol into VTA failed to elevate SMR threshold. Elevations in vocalization thresholds produced by intra-VTA carbachol were reversed in a dose-dependent manner by local administration of the muscarinic receptor antagonist atropine sulfate (30 μg and 60 μg). These results provide the first demonstration of the involvement of the VTA in muscarinic-induced suppression of pain affect.PerspectiveCholinergic activation of the brain reward circuit produced a preferential suppression of rats' affective reaction to noxious stimulation. The neurobiology that relates reinforcement to suppression of pain affect may provide insights into new treatments for pain and its associated affective disorders.     

Antagonism of morphine antinociception by intrathecally administered corticotropin-releasing factor in mice.

Intrathecally (i.t.) administered corticotropin-releasing factor (CRF) has been shown to produce antinociception in the mouse abdominal stretching (writhing) assay. It also has been demonstrated that spinal kappa opioid receptors as well as CRF receptors are involved in the antinociception induced by CRF. In the present study, the role of CRF i.t. in modulating nociception was assessed further using the mouse tail-flick test. In addition, the modulatory effect of i.t. administered CRF on the antinociceptive activity of morphine was studied. Despite its potent and long-lasting antinociceptive effect in the writhing assay, CRF injected i.t. produced no consistent antinociception in the tail-flick test at doses up to 20 times the antinociceptive ED50 of CRF in the writhing test. In contrast, i.t. injection of CRF significantly attenuated the antinociceptive action of s.c. administered morphine. CRF at doses of 0.1 and 0.2 nmol/mouse i.t. increased the antinociceptive ED50 of s.c. morphine by 2- and 4-fold, respectively. The antagonistic action of CRF peaked between 15 min and 1 hr after i.t. injection and was still observable 4 hr after injection, demonstrating a time course similar to that of the antinociceptive effect of CRF in the writhing test. Intrathecal injection of alpha-helical CRF(9-41), a competitive CRF receptor antagonist, was able to inhibit, in a dose-dependent manner, the antagonistic activity of CRF. The antagonistic action of CRF also was attenuated dose-dependently by i.t. injection of nor-binaltorphimine (nor-BNI), a highly selective kappa opioid receptor antagonist. However, intrathecal injection of (+)-1-nor-BNI, an inactive enantiomer of nor-BNI, did not affect the antagonistic action of CRF. These data suggest that spinal kappa opioid receptors as well as CRF receptors are involved in the antagonistic effect of CRF against morphine antinociception.